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Real-time in vivo imaging of invasive- and
biomaterial-associated bacterial infections using
ﬂuorescently labelled vancomycin
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Invasive and biomaterial-associated infections in humans are often difﬁcult to diagnose and
treat. Here, guided by recent advances in clinically relevant optical imaging technologies, we
explore the use of ﬂuorescently labelled vancomycin (vanco-800CW) to speciﬁcally target
and detect infections caused by Gram-positive bacteria. The application potential of vanco-
800CW for real-time in vivo imaging of bacterial infections is assessed in a mouse myositis
model and a human post-mortem implant model. We show that vanco-800CW can speciﬁ-
cally detect Gram-positive bacterial infections in our mouse myositis model, discriminate
bacterial infections from sterile inﬂammation in vivo and detect biomaterial-associated
infections in the lower leg of a human cadaver. We conclude that vanco-800CW has a high
potential for enhanced non-invasive diagnosis of infections with Gram-positive bacteria and is
a promising candidate for early-phase clinical trials.
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B
acterial infections are of mounting medical and public
concern. As human life expectancy continues to increase, so
has the number of frail and immune-compromised
individuals who are susceptible to bacterial infections. A major
contributor to this trend is the proliferation of medical implants
and devices, which are inherently vulnerable to bacterial
contamination. To complicate matters further, current antimi-
crobial therapies face challenges from the emergence of
omnipresent drug-resistant microbes such as methicillin-resistant
Staphylococcus aureus. Infections precipitated by implanted
materials occur at high frequency and are difﬁcult to diagnose
and treat. For example, B5% of the inserted internal ﬁxation
devices in bone fractures become infected. This number rises to
B30% after ﬁxation of open fractures1. Apart from the clinical
implications and burden on the patients’ quality of life, the costs
for treating such severe complications can be as much as $107,000
per case2.
A major challenge in averting biomaterial-associated infec-
tions (BAIs) is the lack of a sensitive, speciﬁc and non-invasive
modality to detect early-stage bacterial infections, when
treatment is most effective owing to the absence of profound
bioﬁlm formation. Currently, only indirect imaging modalities
are in clinical use, as exempliﬁed by positron emission tomo-
graphy with ﬂuoro-deoxy-glucose, which visualizes increased
glucose uptake by inﬂammatory cells3. Alternatively, sites of
inﬂammation can be located by injection of radiolabelled
leukocytes and subsequent scanning. Unfortunately, these
approaches lack sufﬁcient resolution, practicality and cannot
clearly discriminate between a bacterial infection and general
inﬂammation. Therefore, clinical imaging tools that are easy-to-
use, allow bedside monitoring, and directly target invasive
bacteria are highly desirable. Radiolabelled antibiotics are
attractive ligands that directly bind to pathogenic bacteria4.
However, their general use is hampered by inherent limitations
in speciﬁcity and resolution (B0.5 cm) of the radiologic imaging
modality4–7 and radioactivity itself.
Optical imaging, in particular targeted ﬂuorescent imaging
(TFLI), is a relatively novel diagnostic approach that has attracted
increasing support for both preclinical and clinical applications.
TFLI is based on the administration of an exogenous targeting
ﬂuorophore that emits light outside the absorbance window
of bodily tissues. Emitted signals are readily detected by a
sensitive charge-coupled device camera. Clear advantages of
TFLI include the following: (i) non-invasive real-time imaging,
(ii) high resolution, (iii) absence of radiation-related risks and
(iv) relatively low costs. Animal-based experiments have shown
the feasibility of TFLI for detecting tumours. Moreover, the ﬁrst
proof-of-principle study for clinical use of TFLI in ovarian cancer
surgery has been recently reported8.
Recent pioneering studies have demonstrated the feasibility of
TFLI for in vivo detection of bacteria9–11. Before introducing
this approach into the clinic, however, several essential steps need
to be carried out, including toxicity testing of the ﬂuorescent
probe for its clinical translation, according to international
guidelines and standards such as the Good Clinical Practice
guidelines (http://www.ich.org/products/guidelines.html). With
the aforementioned requirements in mind, we propose to use a
novel ﬂuorescent imaging agent derived from the drug
vancomycin as a diagnostic tool for detecting infecting bacteria
in vivo. As vancomycin has been used clinically for over 50 years,
there is widespread familiarity with the pharmacokinetics,
biodistribution and toxicity proﬁle. For usage as an optical
imaging agent to selectively target Gram-positive bacteria in vivo,
we conjugated vancomycin to IRDye 800CW, a near-infrared
(NIR) ﬂuorophore now in early clinical trial (NCT01508572;
Fig. 1a). Vancomycin is a glycopeptide antibiotic drug that
exhibits preferential activity against Gram-positive bacteria,
which are the most prominent causative agents of soft tissue
infections and BAIs. Vancomycin binds speciﬁcally to the D-Ala-
D-Ala moiety present in bacterial cell walls (Fig. 1b). Biodistribu-
tion of a vancomycin-based agent can be similar to that of
unlabelled vancomycin, as shown by single photon-emission
computed tomography studies in rats12. In the present study, we
show that NIR optical imaging with a bacteria-speciﬁc
vancomycin-based probe can detect both invasive infections












































































Figure 1 | Vancomycin-IRDye 800CW and the experimental approach. (a) Structure of vanco-800CW. (b) Schematic representation of the
experimental approach for imaging mice injected with either S. aureus (S. aureus myositis), E. coli (E. coli myositis) or Cytodex beads (sterile myositis),
and subsequent detection of S. aureus with vanco-800CW.
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Results
Detection of clinical bacterial isolates in vitro. To determine the
binding speciﬁcity of vanco-800CW, bacterial isolates from
infected orthopaedic material of 19 patients at the University
Medical Center Groningen were cultured, incubated with vanco-
800CW and subsequently imaged with an IVIS Spectrum.
Notably, these isolates form a representative display of the
microorganisms encountered in BAIs, including S. aureus,
Staphylococcus epidermidis, Corynebacterium species, Strepto-
coccus or closely related bacterial species (Group G Streptococcus
species, Streptococcus mitis and Granulicatella adiacens), Der-
mabacter hominis, Escherichia coli, Klebsiella species, Enterobacter
species and Pseudomonas species. By this ex-vivo ﬂuorescence
imaging approach, all of the 18 tested Staphylococcus isolates were
detected, and also 21 of the 25 tested Gram-positive bacterial
isolates (84%; Supplementary Fig. S1a) were detected. The
Gram-positive isolates with a ﬂuorescent signal below the preset
detection limit (that is, intensity: 105 net counts) mainly consisted
of Corynebacterium species (4/6). In addition, 10 out of 11 Gram-
negative bacterial isolates (91%) were undetectable using the
above parameters, as expected based on the pharmacological
preference of vancomycin for targeting Gram-positive bacteria.
To determine the minimal number of bacteria detectable
by TFLI, a dilution series was performed using a S. aureus
isolate derived from a clinical sample, labelled with vanco-
800CW. The bacteria were then counted using a counting
chamber. In the dilution series, the minimum ﬂuorescence
detection level approximated 1.2 104 net counts. After incuba-
tion with vanco-800CW, B5 106 staphylococci were detected
in 200 ml, corresponding to 2.5 104 staphylococci per mm3
(Supplementary Fig. S1b).
Bacterial myositis in mice. The in vivo applicability of vanco-
800CW was subsequently tested in immunocompetent mice that
had myositis in the left hind limb induced by intramuscular
injection of luciferase-engineered S. aureus. The S. aureus strain’s
constitutive bioluminescence facilitates localization of live bac-
teria by simultaneous imaging of the ﬂuorescence signal derived
from vanco-800CW and luciferase bioluminescence. Two days
after intramuscular inoculation with S. aureus, six mice were
intravenously injected with vanco-800CW (at 0.1, 1, 3 or
5mg kg 1, in which 1mg kg 1 was administered in several
mice, as this was the expected optimal targeting dose). After an
additional 24 h, both bioluminescence and ﬂuorescence imaging
were performed with an IVIS Lumina II imaging system. A strong
NIR ﬂuorescence (NIRF) signal, attributed to vanco-800CW, was
observed to colocalize with the bioluminescence signal in all
administered doses (that is, an intensity of 3.7 105±9.8 104
counts ex vivo at a dose of 1mg kg 1; Supplementary Fig. S2a).
In addition, the bladder gave a strong signal, which was no longer
detectable after draining (Supplementary Fig. S3a). No NIRF
signal was observed in infected mice that did not receive
vanco-800CW. Importantly, in a co-infection experiment
wherein mice were injected with luciferase-engineered S. aureus
in one hind limb and luciferase-engineered E. coli in the other, a
vanco-800CW-speciﬁc ﬂuorescent signal was observed only for
the staphylococcal myositis (Fig. 2a). Ex vivo, the ﬂuorescence
signal also colocalized with the bioluminescence signal (Fig. 2b
and Supplementary Fig. S2b). A signiﬁcant increase in ﬂuore-
scence signal was observed for the infected muscle in comparison
with the contralateral non-infected hind limb (1.0 105±
4.2 104 counts; P¼ 0.007). Infected tissue yielded a target-to-
background (TBR) ratio of 4.2 corrected for background signal,
over the non-infected tissue in the contralateral leg ex vivo.
Notably, although we observed large overlaps between the
bioluminescence and ﬂuorescence signals, the match between
both signals was not 100% (Fig. 2c, Supplementary Fig. S4 and
Supplementary Movie 1). We attribute this to a combination of
factors, including (i) different threshold settings in the biolumi-
nescence and ﬂuorescence imaging; (ii) differences in wavelengths
of the light emitted through bioluminescence (luciferin peak at
490 nm) and NIRF (IRDye800CW peak at 800 nm), which result
in signiﬁcantly different tissue scattering and absorption prop-
erties; and (iii) the fact that only exponentially growing cells are
bioluminescent (Supplementary Fig. S5), whereas staining with
vanco-800CW is independent of the growth phase. Fluorescence
microscopy demonstrated that the ﬂuorescence in the 800 nm
channel was directly related to the presence of vanco-800CW-
labelled staphylococci (Fig. 2d and Supplementary Fig. S6), as also
detected by Giemsa staining and conﬁrmed by ﬂuorescent in situ
hybridization microscopy (Supplementary Fig. S2c,d). In contrast,
no NIR signal was observed for the E. coli cells (Fig. 2d and
Supplementary Fig. S6). Culturing of homogenized infected
muscle tissue after macroscopic optical imaging revealed the
presence of S. aureus (B6.4 107 colony-forming units (CFUs)),
which was conﬁrmed by ex-vivo bioluminescence
imaging. After autopsy, ﬂuorescence signal was also detected in
the kidneys, liver and urine of vanco-800CW-treated mice
(Supplementary Figs S3b and S7), which is consistent with the
strong in vivo bladder signal (Supplementary Fig. S3a) and the
known pharmacokinetic proﬁles of unlabelled vancomycin and
unmodiﬁed IRDye 800CW (both eliminated by the kidneys)13–15.
The heart, spleen, normal muscle and bowel showed no
ﬂuorescence signal above background levels (Supplementary
Fig. S7).
Non-bacterial inﬂammatory myositis in mice. To discriminate a
bacterial infection from a sterile foreign body reaction or aseptic
inﬂammation, the ﬂuorescence signal detected after intravenous
injection of vanco-800CW in mice with S. aureus-induced myositis
(n¼ 6) was compared with that in mice with sterile myositis induced
by implanted Cytodex beads (n¼ 6). Three of the mice injected with
vanco-800CW had S. aureusmyositis in the left hind limb, as well as
contralateral sterile myositis to reliably compare signals within the
same animal. Ex vivo, the muscle tissue with sterile inﬂammation
showed ﬂuorescent signals (1.8 102±0.8 102 counts) compar-
able to those of healthy tissue (1.2 102±0.1 102 counts, P¼ 0.06,
not signiﬁcant; Fig. 3). Again, muscle tissue infected with the luci-
ferase-engineered S. aureus emitted signiﬁcantly higher ﬂuorescence
signals (4.1 102±2.6 102 counts) in comparison with non-
infected contralateral healthy muscle tissue (P¼ 0  008) and tissue
with sterile inﬂammation (P¼ 0.01; Fig. 3a). Furthermore, upon
correction for background signal, the staphylococcal myositis signal
was 2.4-fold stronger than the sterile myositis signal (s.d., 0.15; 95%
conﬁdence interval, 2.1–2.7; Fig. 3c). The presence of sterile
inﬂammation following bead implantation was conﬁrmed by Giemsa
staining and light microscopy, which showed accumulation of
leukocytes around the beads and absence of leukocytes in healthy
muscle tissue (Fig. 3b). No bioluminescent bacteria were found
in cultures from either the non-infected or sterilely inﬂamed
muscle tissue.
Bioﬁlm detection in a human post-mortem implant model. To
investigate whether vanco-800CW could be employed for non-
invasive optical imaging of bacterial bioﬁlms on superﬁcially
implanted medical devices, we performed human cadaver
TFLI experiments (n¼ 2) with bacteria-contaminated implants.
A three-hole osteosynthesis plate (that is, a one-third tubular
plate) was coated with a S. epidermidis bioﬁlm and subsequently
incubated with vanco-800CW (plate 1). Plates without bioﬁlm
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treated with vanco-800CW (plate 2) or plates containing bioﬁlm
without vanco-800CW incubation (plate 3) were used as controls.
The plates were surgically implanted on the ﬁbula of a human
cadaver, followed by standard skin suturing. Subsequently, the
lower leg was imaged in both pseudocolour and ﬂuorescence modes
with a clinical intraoperative multispectral ﬂuorescence camera
system8,16. A strong ﬂuorescence signal from plate 1 was detected
through the skin, whereas neither plate 2 nor plate 3 showed any
signiﬁcant ﬂuorescence signal compared with the background
(Fig. 4a). Corroborating data were obtained with the IVIS Spectrum
imaging system (Supplementary Fig. S8). Subsequent dose–
response analyses with vanco-800CW-preincubated S. aureus
or S. epidermidis cells spotted onto ﬁlter paper and applied to the
distal tibia of the left leg of a human cadaver showed that
the detection limits for these bacteria were 1.25 108 or
1.5 108CFUmm 2, respectively (Fig. 4b). In this case, the bac-
teria were covered with about 8mm of tissue upon skin suturing.
Discussion
Detecting bacterial infections in patients remains a challenging
clinical problem, with potentially devastating consequences
arising from fulminant infections and sepsis. Current non-
invasive diagnostic imaging techniques are handicapped by low
resolution and speciﬁcity due to their shared inability to
discriminate between bacterial infection and sterile (non-
bacterial) inﬂammation4,7. Moreover, these techniques harbour
inherent disadvantages that preclude their incorporation in
bedside monitoring devices for repetitive clinical application in
individual patients. Optical imaging, in particular TFLI imaging,
has shown great potential in applications ranging from cancer
detection to image-guided surgery8,17,18. Both epi-illumination
techniques and novel developments such as opto-acoustics offer
highly promising methods for early detection of bacterial
infections. Three studies have so far been published, describing
in vivo optical imaging of bacterial infections using ﬂuorescent
agents9–11.
Ning et al.9 used a maltodextrin-IR786 conjugate to detect
E. coli, S. aureus, P. aeruginosa and Bacillus subtilis. The
conjugate yielded strong bacteria-speciﬁc signals in rats after
intravenous administration (TBR ratios of 26). The maltodextrin-
IR786 probe was also able to discriminate E. coli infection from
lipopolysaccharide (LPS)-induced sterile inﬂammation. However,
this probe tends to accumulate only in metabolically active








































Figure 2 | In-vivo imaging of bacterial myositis. (a) Imaging of a mouse with E. coli (Xen16)-induced myositis in the left hind limb and S. aureus (Xen36)-
induced myositis in the right hind limb was performed with the IVIS SpectrumCT Imaging System at 8 and 24h after intravenous administration of 1.8mgkg 1
vanco-800CW. Left side: bioluminescence imaging (open ﬁlter, ﬁeld of view (FOV) 12.8 cm, F-stop 1, 30 s acquisition time); right side: ﬂuorescence imaging
(excitation 745nm, emission 840nm, ﬁeld of view (FOV) 12.8 cm, F-stop 2, 0.5 s acquisition time). (b) Excised muscle tissue of the E. coli-infected left leg (left)
and the S. aureus-infected right leg (right) of the mouse shown in a. (c) Micro-computed tomography (CT) imaging of the mouse shown in a with
bioluminescence (BLI; rainbow scale) and ﬂuorescence (FLI; red–yellow scale) coregistration. A ﬂuorescent signal from the bladder is detectable behind the
spine. See Supplementary Fig. S4 and the Supplementary Movie 1 for the separate BLI and FLI images. (d) Fluorescence microscopy of infected muscle tissue.
A cluster of vanco-800CW-labelled Gram-positive cocci (that is, S. aureus) is indicated in the right panel (red) and a chain of Gram-negative rods (that is, E. coli)
is indicated in the left panel (green). DAPI (4’,6-diamidino-2-phenylindole)-stained cell nuclei are labelled green. Scale bar, 10mm. Vanco-800CW imaging:
excitation 710nm, emission 4785nm; DAPI imaging: excitation 360nm and emission 4458nm. See also Supplementary Fig. S6.
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bacteria. Although the authors described bioﬁlm detection using
maltodextrin-IR786, this probe might not detect infections
containing metabolically inactive bacteria. Furthermore, IR786
has not undergone extensive animal toxicity studies, nor is
clinical good manufacturing practice material available. Although
maltodextrin is a common food additive, no intravenous data are
available for humans.
Panizzi et al.10 reported speciﬁc S. aureus endocarditis
detection in mice using ﬂuorescently labelled prothrombin
(prothrombin-AF680). This agent binds to the staphy-
lococcal coagulase produced by S. aureus on the heart valves,
enabling good visualization of S. aureus-induced endocarditis.
Prothrombin-AF680 was pharmacologically inactive and no
signal was observed in areas of sterile endothelial damage. This
suggests that it could be clinically applicable. Nevertheless,
prothrombin may not be completely S. aureus-speciﬁc, as it is
involved in physiological processes, potentially leading to false-
positive results19. Another potential pitfall of this agent is that
staphylococcal coagulase was shown to be expressed only on the
borders of mature vegetation, which may yield inadequate signal.
Importantly, prothrombin will only reveal coagulase-positive
bacteria, which severely limits the spectrum of detectable bacteria.
Although there is experience with the intravenous use of
prothrombin in humans, AF680 also has not yet undergone
extensive animal toxicity studies.
Kong et al.11 demonstrated in vivo detection of Mycobacterium
tuberculosis with a ‘smart’ activatable probe. This probe consisted
of a b-lactam moiety linking a ﬂuorophore to a ﬂuorescence
quencher. After cleavage of the b-lactam ring by b-lactamase, an
enzyme endogenously produced by M. tuberculosis and some
other bacteria, the ﬂuorophore was separated from the quencher
and emitted a signal. Although such smart activatable probes can
potentially deliver higher TBRs in optical imaging, not all bacteria
produce b-lactamase. In addition, none of the dyes used in this
study have undergone extensive animal toxicity studies, which
limits their translational use.
We have shown here that vanco-800CW enables speciﬁc
detection of the main Gram-positive bacteria that cause soft tissue
and BAIs. Treatment of the latter is most effective during early
stages, before extensive bioﬁlm formation has occurred. There-
fore, early detection could improve patient outcome and reduce
healthcare costs. Vanco-800CW could be ideally used in
combination with a multispectral NIR clinical imaging camera
as exempliﬁed in our human post-mortem implant experiments.
This provides high TBRs owing to reduced tissue autoﬂuores-








Figure 4 | Human post-mortem implant model. (a) Osteosynthetic devices
were either uncoated (2) or coated with an S. epidermidis bioﬁlm (1 and 3).
Plates 1 and 2 were incubated with vanco-800CW before surgically applying
each plate onto the ﬁbula of a post-mortem ankle. Subsequent non-invasive
examination of the ankle was performed with a clinical multispectral
ﬂuorescence camera. (b) Vanco-800CW-labelled S. aureus cells were
spotted onto a Whatman paper strip, which was imaged as in a, either
before (left ﬂuorescence panel) or after surgical application onto the distal
tibia of a post-mortem ankle (right ﬂuorescence panel). The tested
amounts of S. aureus applied to the Whatman paper were: 1, 0.63




















































Figure 3 | In-vivo imaging of bacterial myositis and sterile myositis. (a) Imaging of excised tissue was performed with the IVIS Lumina II. Upper panel,
left: bioluminescence detection of bacterial myositis induced with S. aureus Xen29 after injection with vanco-800CW (þ /þ ); upper panel, right:
bioluminescence detection of sterile myositis after injection with vanco-800CW ( /þ ); lower panel, left: NIR detection of bacterial myositis induced with
S. aureus Xen29 after injection of vanco-800CW (þ /þ ); lower panel, right: NIR detection of sterile myositis after injection of vanco-800CW ( /þ ).
Settings for ﬂuorescence measurements: excitation 745 nm, ﬁlter ICG; acquisition time 3 s, binning 4, F-stop 2, ﬁeld of view 12.5 cm; settings for
bioluminescence measurements: excitation block, ﬁlter open, acquisition time 300 s, binning 4, F-stop 1, FOV 12.5. (b) Conﬁrmation of the presence of
leukocytes by microscopy (Giemsa staining). (b, top) non-infected tissue; (b, middle b, bottom) sterile inﬂammation with Cytodex (*) beads (leukocytes
are indicated by black arrows). Scale bars, 200mm (b, top b, middle) and 20mm (b, bottom). (c) Quantiﬁcation of ex-vivo ﬂuorescence signals in tissues of
bacterial myositis, sterile myositis and heart tissue with the IVIS Lumina II (settings as in a). Bars represent the mean of three mice, error bars display the
s.d. Mice treated with vanco-800CW (1mg kg 1; n¼ 3) are represented by red bars and control non-injected mice (n¼ 3) are represented by yellow bars.
Infected tissues yielded a signiﬁcantly higher signal than sterile inﬂammation (*P¼0 01).
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In-vitro analyses showed highly speciﬁc binding of vanco-
800CW to all tested clinical BAI isolates of S. aureus and
coagulase-negative staphylococci. Variable detection of less
common causes of BAI was observed, with good detection of
Streptococcus and Dermabacter species and a lesser detection of
corynebacteria. As expected, Gram-negative bacteria such as
E. coli or P. aeruginosa were not detectable. For S. aureus, the
in-vitro limit of detection was estimated to be 2.5 104 bacteria
per mm3. Notably, we were able to isolate B6.4 107 CFU
of S. aureus from B300–400mg homogenized tissue taken
from the imaged myositic tissue. It has been shown that the
majority of soft tissue infections and abscesses caused by Gram-
positive cocci contain more than 107 CFUml 1, corresponding
to 104 CFUmm 3 (ref. 21). Therefore, vanco-800CW should
allow detection of the vast majority of clinically relevant Gram-
positive bacterial infections in vivo, making it more widely
applicable than prothrombin-AF680 or b-lactamase-speciﬁc
smart activatable probes.
The in vivo efﬁcacy of vanco-800CW was demonstrated in a
mouse model of myositis induced by bioluminescent S. aureus.
The vanco-800CW-speciﬁc signal colocalized with the intrinsic
bioluminescence of the staphylococcal strain and was able to
discriminate S. aureus-induced infection from E. coli-induced
infection or sterile inﬂammation. In terms of biodistribution,
strong ﬂuorescence signals were detected in the kidney and urine;
a minor signal was detected in the liver. These signals suggested
that vanco-800CW was metabolized by the liver into renally
excreted products. It is long known that native vancomycin
is mainly eliminated from the body by renal excretion13. Un-
conjugated IRDye 800CW is also known to be excreted by the
kidneys14,15. Importantly, the signals emitted from infection sites
were clearly distinguishable from the kidney, bladder and liver
signals. No signiﬁcant signal was detected in other organs. As
expected, no bowel signal was observed, as vancomycin was
unable to penetrate the bowel. Therefore, the gut microbiota
should not interfere with imaging of bacterial infections.
A post-mortem study using contaminated implants was
performed as a clinical simulation to assess the feasibility of
BAI detection. S. epidermidis-containing implants stained with
vanco-800CW were visible through the cadavers’ skin. Further-
more, vanco-800CW-labelled S. aureus or S. epidermidis cells
spotted onto implanted paper strips were detectable at levels of
1  25 108 or 1  5 108 CFUmm 2, respectively. Although this
detection limit may seem high, it should be noted that the
bacteria were present in a two-dimensional layer covered by
B8mm of sutured tissue, which mimics the situation in an early-
stage bioﬁlm. In a progressive BAI, bacteria will grow in three
dimensions, which is likely to be more readily detectable, as was
the case in our mouse myositis model. Altogether, our ﬁndings
imply that detection of early-stage bioﬁlm formation on implants
using vanco-800CW is feasible. Nevertheless, limited tissue
penetration might pose a challenge in detecting deeper infections
arising from hip prosthesis or endocarditis, as the current
maximum penetration depth of NIRF is around 1 cm22. Another
challenge could be that the vascularity around synthetic joint
implants may be limited. However, new techniques such as opto-
acoustic imaging may allow deeper tissue penetration to a depth
of several centimetres and at greater sensitivity, potentially
allowing detection of bacterial infections that are seated deeper in
the human body22.
Vancomycin has been extensively applied in the clinic for over
50 years. Using this clinically approved drug as a targeting agent
coupled with IRDye 800CW, which has undergone good
laboratory practice (GLP) toxicity testing and is being used in a
clinical trial (NCT01508572, UMCG), is likely to expedite the
translation of the vanco-800CW agent into clinical use after
appropriate toxicity testing and good manufacturing practice
production according to Good Clinical Practice guidelines23. In
our mouse model, a strong ﬂuorescence signal emanated from the
site of bacterial infection with an intravenous dose of 1mg kg 1
vanco-800CW, which is tenfold lower than the therapeutic dose
in humans (10mg kg 1). Besides, for most clinical imaging
indications, only one single bolus injection of the imaging agent
will be administered. Accordingly, unwanted side effects such as
toxicity or induction of vancomycin resistance in bacteria are
unlikely.
In summary, we have shown that speciﬁc detection of Gram-
positive bacterial infections can be achieved with optical imaging
using vanco-800CW in vivo in a mouse myositis model. We have
also tested vanco-800CW in a human post-mortem BAI implant
model, with the intent of developing a novel bedside tool for
detecting soft tissue infections and BAI. On the basis of the
present ﬁndings, we consider vanco-800CW as a very promising
clinical optical imaging agent for the detection of Gram-positive
bacterial infections. Furthermore, we anticipate that optical
imaging will gain a place in day-to-day clinical practice in the
ﬁght against severe bacterial infections.
Methods
Synthesis of vancomycin-IRDye800CW. Vancomycin-IRDye800CW (vanco-
800CW) was synthesized by an adapted literature procedure24. Vancomycin
hydrochloride hydrate (3.0mg, 2.0 mmol; Sigma-Aldrich, St Louis, USA) was added
to a solution of IRDye800CW-NHS ester (1.0mg, 0.86 mmol; LI-COR Biosciences)
and N,N-diisopropylethylamine (2.0 ml, 11mmol; Sigma-Aldrich) in
dimethylsulphoxide (200 ml; Sigma-Aldrich). The reaction progress was monitored
by analytical reversed-phase HPLC on an Agilent Technologies 1100 Series system
with a Polaris C18-A column (100 3.0mm; ﬂow rate 0.5mlmin 1; manual
injection of 10ml samples; column temperature 30 C). HPLC buffer A was 50mM
triethylammonium acetate, 4% acetonitrile, pH 6.0, and HPLC buffer B was 50mM
triethylammonium acetateþ 80% acetonitrile. The column was equilibrated at 0/
100 Buffer B/Buffer A, and the elution gradient was established from 0/100 to 100/0
Buffer B/Buffer A over 10min (5min post-time to re-equilibrate column). The
monitored wavelengths were 780, 680, 280 and 230 nm. After overnight reaction at
ambient temperature, the resulting bioconjugate was puriﬁed by preparative
reverse-phase HPLC on an Agilent Technologies 1100 Series system with a Zorbax
C18 column (250 9.6mm; ﬂow rate 3.0mlmin 1; manual injection of 100ml
samples, column temperature 40 C). The column was equilibrated at 20/80 Buffer
B/Buffer A, and the elution gradient was established from 20/80 to 35/65 Buffer B/
Buffer A over 15min (10min post-time to re-equilibrate column). The monitored
wavelengths were 780, 680, 280 and 230 nm. The major peak was collected as two
fractions, aliquots of which were checked by ultraviolet–visible spectrometry
(Supplementary Fig. S9) and low-resolution mass spectrometry on an Agilent
Technologies 1100 Series LC MSD Trap (Supplementary Fig. S10) to determine
compound identity, and by analytical HPLC (Supplementary Fig. S11) to determine
compound purity. Within the limits of HPLC detection, the ﬁnal product did not
contain any unconjugated dye (detected at 780 nm) or unlabelled vancomycin
(detected at 280 nm; Supplementary Fig. S12). Fractions containing pure vanco-
800CW were pooled, concentrated in vacuo, redissolved in UltraPure water and
eluted through Amberlyte IR-120 Ion Exchange Resin (sodium form). The bulk
solution of ion-exchanged vanco-800CW was quantiﬁed by ultraviolet–visible
spectrometry on an Agilent 8453 Series spectrophotometer. The isolated yield for
the product was determined to be 1.0mg (46%, 396 nmol). The product was
packaged as 25 nmol aliquots, frozen at  80 C and lyophilized to afford a green
ﬂocculent solid. Ultraviolet–visible (methanol) lmax¼ 778 nm; low-resolution mass
spectrometry (electrospray (ES)/ammonium formate), m/z calculated for 24,307
[M—H] , found 8,106 [M—3H]3 . Before usage, the vanco-800CW was dis-
solved in PBS.
Bioﬁlm formation. The American Type Culture Collection S. epidermidis strain
35984 was plated on agar containing 5% sheep blood and cultured at 35 C, 5%
CO2. A colony was transferred to Tryptic soy broth (TSB)þ 2.5% glucose and cells
were cultivated at 35 C for 2 days under shaking. Finally, a 200-fold dilution of the
S. epidermidis suspension was incubated with an osteosynthetic device (that is, one-
third tubular plate) in TSBþ 2.5% glucose medium overnight at 35 C.
Incubation with vancomycin-IRDye800CW. Bacteria or bioﬁlm-bearing bio-
materials were incubated with TSBþ 2  5% glucose medium containing vanco-
800CW (0.14 nmolml 1) for 2 h at 35 C, 5% CO2. Subsequently, the incubated
material was washed twice with PBS. For bacterial suspensions, the materials were
centrifuged (8min at 16,873 relative centrifugal force) and the supernatants were
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removed. The pellets were resuspended in PBS or TSB. In-vitro imaging analyses
were performed using an IVIS Spectrum (Caliper LS, Hopkinton, MA, USA).
Clinical isolates. Samples of bacterial infections related to orthopaedic bioma-
terial, occurring over 1 year at the UMCG, were collected (2010–2011, 32 patients
with 150 isolates). A selection of variably occurring species was prepared to mimic
microbial populations associated with BAIs. Selected isolates (38 from 19 different
patients) were thawed and cultured on blood agar plates (5% sheep blood) for 3
days at 35 C, 5% CO2. Suspensions at an optical density of 3.5–4.2 McFarland
were prepared, incubated with vanco-800CW and washed twice with PBS. Samples
were centrifuged and pellets were resuspended in 200 ml PBS and pipetted into 96-
well plates (BD Falcon, black). Imaging was performed with the IVIS Spectrum,
using the settings speciﬁed in Figure S1. The experiment was performed twice in
duplicate.
Limit of bacterial detection. To determine the limit of bacterial detection, a
clinical isolate of S. aureus was suspended in TSBþ 2  5% glucose medium (4
McFarland in 2ml). The suspension was incubated with vanco-800CW, washed
twice with PBS and resuspended in PBS. Numbers of bacteria were calculated using
a cell counting chamber (Bu¨rker), at a 200-fold dilution and optical enhancement
with safranin 0  1%. Counting was done independently by two researchers. A series
of dilutions in 180 ml PBS was prepared in black 96-well plates. The experiment was
performed thrice in duplicate with non-treated S. aureus as a negative control.
Imaging analysis was performed with the IVIS Spectrum. After analysis, incubated
S. aureus and non-treated S. aureus were plated on blood agar and cultured
overnight at 35 C, 5% CO2, to determine whether vanco-800CW at the used
dosage would impair viability.
Mouse experiments. Experimental animal studies shown in Fig. 3 and
Supplementary Figs S2, S5, S7 and S9 were performed at the Institut fu¨r Molekulare
Infektionsbiologie, Universita¨t Wu¨rzburg, Wu¨rzburg, Germany. These studies were
approved by the Committee on the Ethics of Animal Experiments of the govern-
ment of Lower Franconia, Germany (55.2–2531.01-06/12), and were performed in
strict accordance with the German animal protection law. Experimental animal
studies shown in Fig. 2, Supplementary Figs S3, S4 and S6, and Supplementary
Movie 1 were performed at the PerkinElmer facility in Alameda, CA, USA. These
studies were approved under the IACUC protocol number 003 (expiry date 1
August 2014). They were carried out by qualiﬁed personnel with strict compliance
to rules and regulations for the PerkinElmer facility in Alameda, to ensure that all
animals were humanely treated.
Bioluminescent S. aureus (Xen29, Caliper LS) was used to induce a hind limb
myositis in 12 Naval Medical Research Institute (NMRI) mice25. The applied dose
of 5 107 CFU per injection was the minimum dose at which a readily detectable
myositis developed (Supplementary Fig. S13). Two days post infection, vanco-
800CW was intravenously administered (0  1–5mg kg 1) to six infected mice and
six non-infected mice. After 24 h, the 12 infected and six non-infected mice were
killed and imaged with an IVIS Lumina II (Caliper LS) to detect ﬂuorescence and
bacterial bioluminescence. In co-infection experiments, NMRI mice were infected
with bioluminescent S. aureus (Xen36) and E. coli (Xen16; Caliper LS) at 5
107 CFU per injection. Low-dose micro-computed tomography (CT) was
performed with a Quantum FX microCT Imaging System within the IVIS
SpectrumCT (Caliper LS). Infected muscle tissue was excised and subsequently
imaged with the IVIS Lumina II or the IVIS SpectrumCT. Infected tissue was
homogenized and cultured or stored at  80 C. Bacterial presence in excised tissue
was visualized either by ﬂuorescence microscopy or by Giemsa staining and light
microscopy. For NIRF microscopy, tissues were ﬁxed overnight with 4%
paraformaldehyde in PBS (pH 7.5) and washed thrice in PBS (10min), twice in
70% ethanol (1 h) and twice in 95% ethanol (1 h). Fixed tissue was embedded in
parafﬁn and 5-mm-thick sections were cut. Deparafﬁnization and rehydration of
tissue slides were performed by washing in xylene (5min, thrice), 100% ethanol
(2min, twice), 96% ethanol (2min), 80% ethanol (2min), 70% ethanol (2min),
50% ethanol (2min), distilled water (2min) and PBS (5min). Vectashield
mounting medium (Vector Laboratories, Burlingame, CA, USA) with DAPI (4’,6-
diamidino-2-phenylindole) was added and a coverslip was placed. Fluorescence
imaging was performed with the Nuance EX multispectral charge-coupled device
camera (PerkinElmer, Hopkinton) and an Eclipse E400 microscope (Nikon, Japan).
For Giemsa staining, frozen tissue sections were made (6 mm thickness) and
mounted on slides. The sections were ﬁxed in methanol for 1min, rinsed with
water, treated with 2  5% Giemsa dilution in PBS for 30min and rinsed with water.
Fluorescent in situ hybridization with an eubacterial (EUB)–ﬂuorescein isothio-
cyanate probe was performed to conﬁrm the presence of bacteria26. Brieﬂy, sections
were ﬁxed with methanol and dried on a hot plate. Next, sections were treated with
permeabilization buffer, rinsed with methanol and dried on a hot plate. The EUB–
ﬂuorescein isothiocyanate probe dissolved in urea buffer (10 ng ml 1) was added to
the sections, followed by incubation for 20min on a hot plate27. The sections were
washed twice, covered with Vectashield (Vector Laboratories) and coverslipped.
Analysis was performed using ﬂuorescence microscopy (Leica CTR5500; Leica
Microsystems BV, Rijswijk, The Netherlands).
To induce a sterile inﬂammation, Cytodex beads (1mg in 50 ml; Sigma-Aldrich)
were injected in the upper leg muscle of four NMRI mice28. Vanco-800CW was
intravenously administered (1mg kg 1) to two mice. To compare the sterile
inﬂammation with bacterial myositis, S. aureus (Xen29) was introduced to the left
hind limbs of six mice, whereas Cytodex beads were introduced into their
contralateral right hind limbs. Three mice were treated with vanco-800CW
(1mg kg 1) and compared with three negative controls. Imaging was performed
with the IVIS Lumina II, and tissues were collected as described above. Frozen
tissue sections were made and Giemsa-stained to conﬁrm leukocyte inﬁltration. To
determine the staphylococcal burden of infected muscles, tissue was aseptically
collected at indicated time points and homogenized in 2ml of sterile PBS using
Dispomix (Bio-Budget Technologies GmbH, Krefeld, Germany). Serial dilutions of
the homogenates were cultured on mannitol salt–phenol red agar plates for at least
48 h at 37 C. Colonies were counted and staphylococcal burden was calculated as
total CFU/excised tissue. Bioluminescence signal was determined using the IVIS
Lumina II.
Human post-mortem implant model. Bioﬁlms were formed on two osteosynthetic
devices (one-third tubular plates) by incubation with S. epidermidis ATCC 35984.
Subsequently, bioﬁlm-coated plates and uncoated control plates were incubated
with vanco-800CW as mentioned above and washed twice with PBS. The three
differently treated osteosynthetic devices were implanted on the distal ﬁbula in a
human cadaver ankle and the skin was subsequently sutured (Ethilon 3-0, Ethicon
Somerville, NJ, USA). Imaging was performed using an intraoperative clinical
multispectral ﬂuorescence camera (T3-imaging system, SurgOptix BV, Groningen,
The Netherlands) and the IVIS Spectrum8,16. The experiment was performed twice
with the lower legs of two human cadavers. For dose–response measurements,
dilution series of vanco-800CW-treated S. aureus SH1000 or S. epidermidis ATCC
35984 were spotted on Whatman 3MM paper strips (ranging from 2.5 104 to
2.5 108 CFUmm 2, or from 1.5 104 to 1.5 108 CFUmm 2, respectively).
These were subsequently implanted on the medial site of the distal tibia in a human
cadaver ankle, and imaging was performed with the T3 intraoperative clinical
multispectral ﬂuorescence camera. The post-mortem experiments were conducted
according to institutional guidelines with prior approval from the scientiﬁc review
committee of the Skills Center of the University Medical Center Groningen, The
Netherlands. All individuals involved in the human post-mortem studies have
provided informed written consent for the use of their bodies for scientiﬁc research
and teaching.
Software. Results obtained with the IVIS systems were analysed with Living Image
4  2 (Caliper LS). Optimal detection limits were set to the lowest signal at which the
positive signal was effortlessly discriminated from negative controls. Signal
intensity was determined by drawing regions of interests and measuring average
counts in these regions. The signal was corrected for background by subtracting the
background signal from the signal of interest, referred to in the text as net counts.
Statistics. Fluorescence imaging data derived by the IVIS systems are expressed in
counts as mean±2 s.d. in the regions of interest. For determining statistical
relationships among bacterial infection, sterile inﬂammation or negative controls,
either the paired or unpaired two-sample Student’s t-test (Po0.05) was used.
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